- AbCellera stock has continued to struggle of late given the absolutely terrible sentiment in the biotech market, however the company's actual business is thriving under the surface.
- In the Q1 earnings call, the company highlighted both the internally developed T-Cell engager platform, along with the Empirico deal which provides the option to co-invest in programs.
- The company is currently sitting on a mountain of cash, $786 million worth and this balance looks to grow further with $334 million in accrued receivables from bebtelovimab.
- Insiders clearly appreciate the opportunity ahead as the CEO, CFO & COO each purchased significant amounts of stock directly after the Q1 release and insiders now own over 27% of the business.
For further details see:
AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying